...
首页> 外文期刊>Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association >Optimizing Anti-TNF-alpha Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
【24h】

Optimizing Anti-TNF-alpha Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

机译:优化抗TNF-α疗法:炎性肠病患者的英夫利昔单抗和阿达木单抗的血清水平与黏膜愈合有关

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND & AIMS: It is not clear what serum levels of anti-tumor necrosis factor are associated with reduced intestinal inflammation in patients with inflammatory bowel disease (IBD). We aimed to identify serum levels of infliximab and adalimumab associated with mucosal healing in patients with IBD and to evaluate the putative gain in control of inflammation by incremental increases in drug levels.
机译:背景与目的:目前尚不清楚哪种血清抗肿瘤坏死因子水平与炎症性肠病(IBD)患者的肠道炎症减轻相关。我们旨在确定与IBD患者黏膜愈合相关的英夫利昔单抗和阿达木单抗的血清水平,并通过药物水平的逐步提高来评估推定的炎症控制作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号